AI Analysis | Feedback

Kezar is like an early-stage Amgen or Biogen, but specializing in novel small molecule drugs for autoimmune diseases and cancer.

Think of it as a specialized Regeneron, focused on discovering and developing innovative small molecule treatments for severe autoimmune conditions and certain cancers.

It's like a pre-commercial Moderna, but developing new small molecule drugs for autoimmune diseases and cancer rather than vaccines.

AI Analysis | Feedback

• KZR-616: A selective immunoproteasome inhibitor currently in Phase 2 and Phase 1b clinical trials for various immune-mediated diseases such as lupus nephritis, dermatomyositis, polymyositis, and systemic lupus erythematosus.
• KZR-261: A novel first-in-class protein secretion inhibitor currently in preclinical development.
• KZR-TBD: A preclinical product candidate being developed for the treatment of oncology and immunology.

AI Analysis | Feedback

Kezar Life Sciences (KZR) is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule therapeutics. As per the provided description, its product candidates (KZR-616, KZR-261, KZR-TBD) are in various stages of clinical trials (Phase 1b, Phase 2) or preclinical development.

Because the company's products are still in clinical development and have not yet received regulatory approval for commercial sale, Kezar Life Sciences does not currently have major commercial customers purchasing its therapeutic products. Its primary activities revolve around research, development, and conducting clinical trials rather than commercial sales.

Therefore, Kezar Life Sciences does not sell primarily to other companies or individuals at this stage of its operations.

AI Analysis | Feedback

AI Analysis | Feedback

Christopher Kirk, PhD, Chief Executive Officer, Co-Founder

Christopher Kirk is the Co-Founder and Chief Executive Officer of Kezar Life Sciences, appointed to the CEO role in November 2023, having previously served as President and Chief Scientific Officer. Prior to co-founding Kezar in 2015, Dr. Kirk was the Vice President of Research at Onyx Pharmaceuticals, where he played a key leadership role in the discovery and development of two proteasome inhibitors, including carfilzomib (KYPROLIS™), which is approved for the treatment of multiple myeloma.

Marc Belsky, Chief Financial Officer

Marc L. Belsky has served as Chief Financial Officer and Secretary of Kezar Life Sciences since April 2018. Before joining Kezar, from October 2009 to April 2018, Mr. Belsky held several roles at Five Prime Therapeutics, Inc., a publicly held biopharmaceutical company, including most recently as Senior Vice President and Chief Financial Officer. Prior to that, he served in various roles at Cell Genesys, Inc., a biotechnology company that was acquired by BioSante Pharmaceuticals, Inc. He also held positions at Active Aero Group, Inc., DataWave Systems Inc., and Michigan National Corporation, a holding company for Michigan National Bank, which was acquired by BANA Holding Corporation. Mr. Belsky began his career as an auditor with Coopers & Lybrand and is a Certified Public Accountant.

Mark Schiller, Chief Operating Officer

Mark Schiller is the Chief Operating Officer at Kezar Life Sciences. Before joining Kezar, Mr. Schiller was the Executive Director, Legal Affairs at Immune Design, a public biotechnology company, from October 2014 until its acquisition by Merck in March 2019. He also led the legal function at 3-V Biosciences, a privately held biotechnology company. Mr. Schiller began his legal career at Gunderson Dettmer LLP, a venture-capital firm, and later worked as a corporate associate at Cooley, LLP, a life sciences and technology law firm.

Nick Mordwinkin, PhD, PharmD, Chief Business Officer

Nick Mordwinkin was appointed as Chief Business Officer of Kezar Life Sciences in July 2023.

AI Analysis | Feedback

1. Clinical Development and Regulatory Approval Failure: Kezar Life Sciences is a clinical-stage biotechnology company, meaning its success is highly dependent on the successful development and regulatory approval of its product candidates. The company's lead candidate, KZR-616, is in Phase 2 clinical trials, and other candidates are in even earlier preclinical stages. There is a significant risk that these product candidates may fail to demonstrate efficacy or safety in clinical trials, experience delays, or fail to receive necessary regulatory approvals, which would severely impact the company's business prospects.
2. Commercialization and Market Acceptance Risk: Even if Kezar's product candidates successfully complete clinical trials and receive regulatory approval, there is no guarantee they will achieve market acceptance or be commercially viable. The markets for immune-mediated diseases and cancer are highly competitive, with established treatments and companies. Factors such as pricing pressure, reimbursement policies, manufacturing capabilities, and competition could hinder the successful commercialization of any approved products.
3. Funding and Capital Requirements: As a clinical-stage biotechnology company without any approved commercial products, Kezar Life Sciences relies heavily on its ability to obtain sufficient funding to continue its research and development activities, clinical trials, and potential commercialization efforts. Developing novel therapeutics is a capital-intensive process, and the company may need to raise additional capital through equity or debt financings, which could result in dilution to existing shareholders or unfavorable financing terms.

AI Analysis | Feedback

AI Analysis | Feedback

Kezar Life Sciences (KZR) is developing KZR-616, a selective immunoproteasome inhibitor, for several immune-mediated diseases. The addressable markets for these main product candidates are detailed below:

• Systemic Lupus Erythematosus (SLE): The global systemic lupus erythematosus market size was valued at approximately USD 2.60 billion in 2023 and is projected to reach USD 4.26 billion by 2030. Another estimate placed the global market at USD 2.7 billion in 2023, growing to USD 6.8 billion by 2035. In the seven major markets (7MM), the market was around USD 3,200 million in 2023, with the United States accounting for approximately USD 2,600 million.
• Lupus Nephritis (LN): The global lupus nephritis market size was USD 2.3145 billion in 2024 and is projected to reach USD 4.177 billion by 2031. Another report valued the global market at approximately USD 1.24 billion in 2023, with a projection to reach USD 2.17 billion by 2032. The market size in the seven major markets (7MM) was estimated to be around USD 1,800 million in 2024 and approximately USD 1,958 million in 2025. In the United States, the lupus nephritis market size was USD 730.46 million in 2024. The combined systemic lupus erythematosus and lupus nephritis market across the 7MM is anticipated to grow from USD 2.4 billion in 2024 to USD 5.9 billion in 2034.
• Dermatomyositis: The market size for dermatomyositis in the seven major markets (7MM) was approximately USD 187 million in 2023. The United States market for dermatomyositis was approximately USD 117.6 million in 2023. The global dermatomyositis market size was valued at USD 573.4 million in 2024 and is estimated to reach USD 931.57 million by 2033.
• Polymyositis: The market size for polymyositis in the seven major markets (7MM) was approximately USD 114 million in 2023, with the United States accounting for approximately USD 86 million. The global polymyositis treatment market size was USD 1,290.04 million in 2024 and is anticipated to reach USD 1,952.34 million by 2032. North America led the polymyositis treatment market in 2024 with a value of USD 514.46 million.

AI Analysis | Feedback

For Kezar Life Sciences (KZR), a clinical-stage biotechnology company, expected drivers of future revenue growth over the next 2-3 years are primarily tied to its pipeline progression and strategic partnerships, rather than immediate product sales, as analysts generally forecast zero product revenue during this timeframe.

1. Milestone and Royalty Payments from KZR-261 Divestment: Kezar Life Sciences recently divested its Sec61-based discovery and development program, including the preclinical candidate KZR-261, to Enodia Therapeutics. Under this agreement, Kezar received an upfront payment and is eligible for up to $127 million in development, regulatory, and commercial milestone payments, along with single-digit tiered royalties on future net sales of products derived from these assets. These potential payments represent a concrete driver of future revenue.
2. Successful Clinical Development and Regulatory Progress of Zetomipzomib (KZR-616): The company's strategic focus is on advancing its lead product candidate, zetomipzomib (KZR-616), through clinical trials for various autoimmune diseases, including lupus nephritis, dermatomyositis, polymyositis, and systemic lupus erythematosus. Positive outcomes from these ongoing Phase 2 and Phase 1b trials, along with subsequent regulatory approvals, would be critical for eventual product commercialization or lucrative licensing deals, driving future revenue growth. The recent lifting of the partial clinical hold for KZR-616 in autoimmune hepatitis and the potential full removal for lupus nephritis are positive indicators that could facilitate further development.
3. Formation of New Strategic Collaborations and Licensing Agreements: As a clinical-stage company without commercial products, Kezar Life Sciences actively explores strategic collaborations and licensing opportunities to support its development programs. Such agreements for KZR-616 or other pipeline assets could generate upfront payments, research funding, and future milestone and royalty payments, thereby contributing to revenue growth.
4. Expansion of Zetomipzomib (KZR-616) into New Indications: Broadening the therapeutic applications of KZR-616, particularly by successfully pursuing additional indications beyond its current trial scope, could significantly expand its market potential. This expansion could attract further investment, partnerships, and ultimately lead to a larger addressable market for the drug upon commercialization, driving long-term revenue.

AI Analysis | Feedback

Share Repurchases

No information available for share repurchases or authorized future share repurchases within the last 3-5 years.

Share Issuance

• Kezar Life Sciences conducted a one-for-ten reverse stock split, which became effective on October 29, 2024.
• This action reduced the outstanding common stock from approximately 72.96 million shares to about 7.30 million shares.
• The primary purpose of the reverse stock split was to regain compliance with Nasdaq's minimum bid price requirement for continued listing.

Inbound Investments

• Kezar Life Sciences recognized $7.0 million in collaboration revenue in 2023, which was its first reported revenue.
• This revenue originated from an upfront payment under a license agreement with Everest Medicines, reported for the fiscal year ended December 31, 2024.
• Future revenues from this agreement may include milestone and royalty payments contingent on regulatory and commercial achievements.

Outbound Investments

• On March 12, 2026, Kezar Life Sciences sold its Sec61-based discovery and development program, including preclinical candidate KZR-261, to Enodia Therapeutics.
• Kezar received an initial payment of $800,000 at closing, with an additional $200,000 due related to inventory delivery or 45 days after closing.
• The agreement includes potential development, regulatory, and commercial milestone payments of up to $127,000,000, along with single-digit tiered royalties on future net sales of products from the acquired assets.

Capital Expenditures

• Capital expenditures were reported as -$19K in the last 12 months (prior to February 15, 2026).
• For 2023, capital expenditures were -$1.8 million.
• The company's operations are characterized as "capex-light".